Omega Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Omega Therapeutics, Maintains $12 Price Target
Omega Therapeutics Analyst Ratings
Chardan Adjusts Price Target on Omega Therapeutics to $7 From $6, Maintains Buy Rating
Omega Therapeutics Analyst Ratings
HC Wainwright & Co. : The Omega Therapeutics (OMGA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
Omega Therapeutics Analyst Ratings
Buy Rating Reaffirmed for Omega Therapeutics on Strong Clinical and Financial Performance
Analysts' Top Healthcare Picks: Fresenius Medical Care AG & Co. KGaA (GB:0H9X), Omega Therapeutics (OMGA)
Chardan Capital: Maintains Omega Therapeutics (OMGA.US) rating, adjusted from buy to buy rating, and adjusted target price from $7.00 to $7.00.
Omega Therapeutics Analyst Ratings
Chardan Capital Maintains Buy on Omega Therapeutics, Maintains $7 Price Target
Buy Rating Affirmed for Omega Therapeutics Amid Strong Financials and Promising OTX-2002 Clinical Trials
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
HC Wainwright & Co. : The Omega Therapeutics (OMGA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $12.00.
Omega Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Omega Therapeutics, Maintains $12 Price Target
Omega Therapeutics Analyst Ratings
Omega Therapeutics (OMGA) Receives a Buy From Piper Sandler
Omega Therapeutics Analyst Ratings